The ICAM is a successful partnership between bp, The University of Manchester, University of Cambridge, Imperial College London and the University of Illinois Urbana-Champaign. Since its launch in 2012, the ICAM has supported research ranging from PhD-led exploratory projects to large-scale strategic initiatives involving multiple teams. The Centre has strengthened research capabilities, fostered interdisciplinary collaboration and provided students and early career researchers with valuable experience working alongside bp experts. Its model embeds bp Mentors within project teams, ensuring research remains industrially relevant and accelerates translation from laboratory to application.

The ICAM’s Next Chapter

Building on more than a decade of interdisciplinary research in materials science, the ICAM will continue to make a difference in today’s energy systems and help build tomorrow’s, while aligning with bp’s strategic interests and technology roadmaps.

The ICAM’s research supports bp’s ambition to be a net zero company and to help get the world to net zero by 2050 or sooner by improving understanding of materials, processes and energy systems that can lower emissions and enhance performance. Recent examples include research on sustainable catalysts for CO₂ conversion through the ICAM's EPSRC Prosperity Partnership on Sustainable Catalysis for Clean Growth, and work to develop better modelling tools for sustainable aviation fuel.

In recent years, the ICAM has welcomed additional expertise from associate members including Cardiff University and Johnson Matthey, both central to its previously mentioned Prosperity Partnership as well as University College London, University of Edinburgh, University of Leeds, University of Sheffield and University of Texas at Austin.

In its next chapter, the ICAM will continue to exemplify what can be achieved when industry and academia work together to address energy challenges.

Key findings

• A grammar-based authorship analysis method matched or exceeded leading AI systems across most test datasets
• The approach outperformed several neural network-based authorship verification models
• Researchers tested the method across 12 real-world writing datasets including emails, forums and reviews
• The system is more transparent than many AI models because it shows which grammatical patterns informed decisions
• Researchers say the findings challenge assumptions that more complex AI always produces better results

What did the study find?

Researchers found that a relatively simple, linguistically grounded method can perform as well as - and in some cases better than - complex artificial intelligence systems in identifying authorship.

The study suggests that increasingly sophisticated AI is not always necessary for high-performing writing analysis, particularly when methods are designed around established principles of how language works.

How does the LambdaG method work?

The method, called LambdaG, analyses patterns in grammar rather than relying on large-scale machine learning models.

It builds a statistical profile of how an individual writes by measuring features such as function word usage (words like it, of and the), sentence structure, punctuation patterns and other grammatical habits.

The researchers say these features create a distinctive behavioural signature for each writer.

Why is this different from AI-based authorship analysis?

Many current authorship verification systems rely on complex AI models trained on vast datasets. While effective, these systems can be difficult to interpret, computationally expensive and hard to explain in high-stakes settings such as legal investigations. By contrast, LambdaG provides a transparent explanation of which grammatical features influenced its conclusions.

How accurate was the method?

Researchers tested LambdaG across 12 datasets designed to reflect real-world writing scenarios, including emails, online forum posts and consumer reviews.

In most cases, the method achieved higher accuracy than several established authorship verification systems, including neural network-based approaches.

Why does grammar reveal authorship?

The researchers argue that grammar acts as a behavioural signature, like how we write our signature or how we walk.

Over time, individuals develop unconscious habits in how they structure sentences and use language. These habits create identifiable linguistic patterns that can distinguish one writer from another.

What are the potential applications?

The researchers say the method could support work in:

• Forensic linguistics
• Criminal investigations
• Online abuse detection
• Academic integrity monitoring

The study was published in Humanities and Social Sciences Communications.

DOI:

Fifty researchers from institutions  around the world -  including the University of Manchester - have issued the alert in calling for urgent action to stop fungal infections becoming untreatable.

They say fungi in soil, crops and hospitals are increasingly resistant to the medicines used to control them.

For most healthy people this poses little danger, but for patients with weakened immune systems the infections can be deadly.

Global strategies to tackle antimicrobial resistance have focused too heavily on bacteria and viruses while largely overlooking fungi, they argue.

To combat it, they have produced a five‑step plan to improve awareness, surveillance, infection control, responsible drug use and investment in new treatments.

The plan is intended to help shape the World Health Organization’s updated Global Action Plan on antimicrobial resistance later this year.

Scientists warn that several dangerous fungi are already spreading, including Trichophyton indotineae, which causes severe skin infections that are increasingly hard to treat.

Hospitals are also battling Candida auris, a fungus that can trigger life‑threatening bloodstream infections and kills around a third of those affected.

Another concern is Aspergillus fumigatus, a common mould that has developed resistance to widely used azole drugs in many countries.

Experts say much of this resistance begins not in hospitals but in the environment.

Fungicides used in agriculture are chemically similar to antifungal medicines used in human healthcare, allowing resistant strains to evolve in fields before reaching patients.

This link between environmental, agricultural and medical use — known as One Health — means resistance in crops can undermine treatments for people.

Researchers say coordinated action across science, farming, healthcare and policy is now essential to protect both global food supplies and patient safety.

They point to early initiatives, including the WHO’s fungal priority pathogen list and new One Health working groups, but warn these efforts must be embedded in global antimicrobial resistance policies.

The authors are urging governments and international bodies to prioritise antifungal resistance before more infections become untreatable.

“Farmers use huge amounts of fungicides to protect crops, and some of these chemicals stay in the environment for decades,” said Professor from the University of Manchester.

“There is now clear evidence these chemicals are helping fungi evolve into strains that can no longer be treated in people, plants or animals.”

“If we don’t act, we will see more infections that simply can’t be cured, which puts lives and food supplies at risk,” he added.

Professor Paul Verweij from Radboud University Medical Center in the natherlands, said: “We are already seeing a quiet rise in dangerous fungi, from Candida auris in intensive care units to moulds in the community that no longer respond to standard medicines.

“Unless antifungal resistance is included in the WHO’s 2026 global plan with proper funding and targets we risk repeating the same mistakes made with antibiotic resistance.

“Using the same types of antifungal chemicals in both farming and medicine is speeding up resistance, and what happens in the fields is now affecting what happens in hospital wards,” added  Professor Michaela Lackner of the Medical University of Innsbruck.

• Image: aspergillus fumigatus. Credit Isabelle Storer
• Closing the gap on fungal resistance is published in  https://doi.org/10.1038/s41591-026-04334-5

Routine monitoring of fibre release is considered essential for designing more sustainable textiles and informing policies aimed at reducing pollution at source. However, existing methods are time consuming, prone to bias and vulnerable to contamination. 

By adapting industrial dyeing techniques used in textile manufacturing and combining them with established microplastic analysis methods, the research bridges fashion technology and environmental science to overcome these barriers. The result is a faster, more reliable way to measure microfibre emissions under real world conditions such as washing and mechanical stress. 

The researchers say the method could support better eco-design of textiles, improve testing standards and inform future regulation – including policies such as extended producer responsibility. It may also help guide the development of technologies designed to capture fibres, such as washing machine filters. 

“If we want to reduce microfibre pollution, we need reliable ways to measure it,” Dr Allen added. “This approach opens the door to routine testing that reflects what’s really being released into the environment – not just what’s easiest to see.”

The findings, published today in  journal BBA: Molecular Basis of Disease  shed new light on ocular coloboma, a rare congenital eye condition affecting around 1 in 5000 births and responsible for roughly 10% of childhood blindness.

Some of the researchers are also based at 91ֱ�� University NHS Foundation Trust  and the Greenwood Genetic Centre in the United States.

Coloboma arises when a structure in the developing eye, the optic fissure, fails to close properly and often co‑occurs with other tissue‑fusion problems such as cleft lip and/or palate.

The research focused on YAP1, a protein that helps guide how organs form and how tissues stay healthy.

YAP1 acts like a switch inside cells, helping them decide when to grow, change, or survive based on signals they receive.

Although changes in YAP1 have been linked to coloboma, it has been unclear why some people with these changes develop severe eye defects while others remain unaffected. To address that, they tested the different variants and compared their effects.

To understand the consequences of YAP1’s inactivity during eye development, the researchers studied human retinal organoids - lab-grown miniature versions of the developing human retina grown in the lab. When they reduced the activity of YAP1, they saw effects on how early retinal cells grow and develop.

Disrupting YAP1, they found,  reduced the activity of genes needed for early retinal cells to grow and maintain their identity.

 As a result, the cells developed more slowly, providing a potential explanation for how eye formation goes wrong.

The study also showed that not all YAP1 variants have the same effect. Using computer modelling alongside experimental data, the researchers found that the precise location of each genetic change determines how strongly it disrupts YAP1 function.

This helps explain why coloboma can vary so widely between individuals, even among those carrying changes in the same gene.

Coloboma has been linked to disease causing variants in more than 40 genes, but thanks to the study, YAP1 is now identified as  an important contributor.

“These findings give us a much clearer picture of how small genetic changes can have major effects during eye development,” said the lead author from The University of Manchester.

“By pinpointing how each variant disrupts YAP1’s function, we can better interpret genetic results in patients and move closer to ways of supporting healthy eye formation.

“By combining stem‑cell models with detailed genetic testing, we’re finally beginning to understand how tiny changes in YAP1 can have such a big impact on how the eye forms.

“This work brings us a step closer to explaining why some children develop coloboma.

“Though retinal organoids cannot currently replace the use of animal models, this study shows how they can help us meet our ethical and legal obligations to replace, reduce and refine the use of animals in research wherever feasible.

“It also offers a new framework for understanding how likely YAP1 mutations are to cause disease in children with unexplained eye conditions.”

• Domain-specific mechanisms of YAP1 variants in ocular coloboma revealed by in-vitro and organoid studies is available DOI:

• Image: retinal organoid

The initiative, called KOKU Bladder, brings together evidence‑based education, pelvic floor muscle training, behaviour change techniques and gamification to support engagement and long‑term adherence.

The programme is designed for people to use independently at home while also complementing face‑to‑face care delivered by healthcare professionals.

Pelvic health plays a vital role in healthy ageing, helping people maintain mobility, dignity, independence and overall quality of life.

Urinary incontinence affects more than 14 million people in the UK and between 55 and 60 million across Europe.

Around one in three adults over 60 experience urinary incontinence, rising to nearly half of those aged 80 and above.

Despite its scale and impact, incontinence remains one of the most under discussed and under treated health conditions, often hidden due to stigma, embarrassment and fragmented services.

Professor  Javier Jerez‑Roig from the University of Vic, Principal Investigator, said: “KOKU Bladder is not just another digital tool; it is a solution shaped directly by the people who will use it and the professionals who support them.”

Professor  Emma Stanmore from The University of Manchester is CEO of KOKU Health, a UK digital health company which originated as a research project at the University of Manchester 

As a university spin-out, KOKU translates academic research into a practical tool designed to reduce falls, improve mobility, and support people to live healthier, more independent lives at home.

She added: “By embedding gamification within a clinically credible framework, we aim to make self‑management both motivating and meaningful.”

Although several digital pelvic health tools already exist, a recent review identified only four evidence‑based solutions that include people over 50, and none have been genuinely co‑designed with end users and professionals.

In 2025, a total of 54 people across Spain, Lithuania and the UK contributed to the co‑design of KOKU Bladder, including 31 potential users, 15 healthcare professionals and eight experts in pelvic health and ageing.

Participants highlighted the need for clinically trustworthy content, adaptive pelvic floor training, meaningful personalisation, multimedia guidance and embedded behaviour change techniques such as goal setting, self‑monitoring and feedback.

KOKU Bladder is now in its pilot phase, with 75 participants testing the platform across English, Spanish and Lithuanian versions.

The next stage of the project will be an experimental study beginning this summer in 91ֱ��, led by The University of Manchester to formally evaluate feasibility, engagement and user experience.

The study, published today in the Journal of the American Chemical Society (JACS), describes how the research team, led by Professors and , used directed evolution to develop a bespoke aminotransferase, a type of enzyme, to significantly accelerate the manufacturing process and reduce production costs. This new biocatalytic route has the potential to improve global access to this important medicine.

Lenacapavir, recently approved by the FDA and MHRA, is a twice‑yearly injectable drug that has shown extremely high levels of protection in pre‑exposure prophylaxis (PrEP) trials. Royalty‑free licence agreements are already in place to enable generic manufacturers to supply Lenacapavir to 120 lower‑income countries, yet the high cost of producing its active pharmaceutical ingredient remains a major barrier to widespread availability.

A sustainable route to a complex molecule

Made up of four distinct building blocks, Lenacapavir’s highly functionalised central core is a very challenging building block to synthesise. This core is constructed from a chiral amine that can exist in two mirror-image forms (like a left and a right hand). The handedness – or chirality – is important in pharmaceuticals as only one form of the molecule will work as intended.

Currently, Lenacapavir is made via traditional multi-step chemical synthesis, but due to the central core’s chirality and challenging molecular structure it is a costly and time-consuming process. Biocatalysis offers significant potential for faster and cheaper production.

To achieve this, the MIB team focused on using directed evolution – a method that speeds up nature’s trial-and-error evolution process – to develop an enzyme that could catalyse the target reaction to produce the chiral amine core. Using an approach known as substrate walking, the researchers began with an aminotransferase that showed no detectable activity on the desired substrate. Over eight rounds of directed evolution, involving screening more than 12,000 enzyme variants, they installed ten mutations that progressively unlocked activity, improved stability and reshaped the active site of the enzyme so that it could accept the central amine core’s bulky ketone precursor.

The final enzyme performed exceptionally well, converting 98% of the starting substrate, producing a yield of more than 90% with a purity of over 99% enantiomeric excess (e.e.) meaning that the correct chiral form was produced. The researchers also tested the enzyme under industrially relevant conditions showing its potential to work at scale.

The team also used X-ray crystallography to create a detailed 3D picture of the improved enzyme showing how the molecular changes arising from evolution allowed the enzyme to accept the substrate and transform it into the target product. Understanding the enzyme’s structure helps scientists unpick its mechanism of action which allows them to improve future enzyme design campaigns.

Towards large‑scale implementation

The team is now collaborating with industrial partners to translate the methodology from laboratory scale to industrial biomanufacturing. The details of this new manufacturing route are also freely available for companies to use. Any company interested in producing Lenacapavir via this new process can contact to request free samples of the enzyme. If implemented at scale, the process could enable a shorter, cleaner and more economical production route for Lenacapavir, supporting ambitions to make long‑acting HIV prevention accessible worldwide.

Figures for 2025 show the Museum welcomed 648,595 visitors throughout the year, meaning it continues to buck the trend, in the face of an overall decline in visitor numbers since 2019.

91ֱ�� Museum's visitor numbers are up 76% over that period, compared with a decline of 7% across all ALVA member sites.

The total number of visits to 409 ALVA sites in 2025 was 165 million. This did, however, represent a 2% increase on the previous year.

Since reopening in February 2023, following a £15 million redevelopment, has seen impressive growth in audiences, driven by exciting new gallery spaces, special exhibitions such as The Cat That Slept for a Thousand Years, a rich and diverse events programme and engagement with schools across Greater 91ֱ��.

The Vivarium is a centre for globally-significant conservation projects, caring for around 30 different amphibian and reptile species, many of which are critically endangered. It has sat at the heart of Manchester Museum for more than 60 years, growing out of work by researchers at the University of Manchester to inspire generations of visitors.

91ֱ�� is the only place outside the Americas where you will find the Variable harlequin toad (Atelopus varius). The Museum Museum houses the world’s only captive ‘back-up’ population, thanks to a pioneering partnership with Panama Wildlife Conservation Charity, just one of many projects designed to safeguard the future of endangered species and develop learning programmes that raise awareness of threats to biodiversity.

Scheduled for completion in Spring 2027, the ‘Habitats of Hope’ development promises to connect museum audiences with this world-class care, research and international collaboration.

Funding will help to revitalise public displays and create new, state-of-the art facilities and bespoke naturalistic environments for the amphibian and reptile species cared for by the Vivarium. It will also allow the development of dedicated facilities for schools teaching and visiting tour groups, further enhancing the gallery’s potential for learning.

The Museum will also create new permanent displays that explore the connections between its wider collections and the animals it cares for, celebrating the deep ties between reptiles, amphibians and people, and revealing how these animals have shaped human cultures and understanding.

Georgina Young, Head of Collections and Exhibitions at 91ֱ�� Museum, said: “Habitats of Hope speaks to how wonderful and how vulnerable the world’s rarest amphibians are. Major investment from the DCMS/Wolfson Museum and Galleries Improvement Fund means 91ֱ�� Museum can match the highest standards of animal care with a more accessible visitor experience, while weaving stories of research, conservation, partnership and action that stretch from thriving ponds in 91ֱ�� to hyper-biodiverse ecosystems in Costa Rica and Panama.”

The Habitats of Hope project is expected to commence in December 2026 and complete in April 2027. The Vivarium will close during this period.

The study, published in PLOS Mental Health comes as Colombia has taken steps to expand healthcare access to some of the 2.86 million Venezuelans in the country, including offering temporary protection status.

However large numbers of the migrants are ineligible for protection, particularly those with irregular status who can only access emergency services or limited humanitarian programmes while discrimination and administrative barriers persist.

Led by GP Dr John Fitton, the study was adapted from his Master of Public Health dissertation at The University of Manchester. He is now a PhD student at University College London.

Nariño, on the Ecuadorian border, is a major crossing point for Venezuelan migrants fleeing economic collapse, political instability, food insecurity, and breakdown of health and social services.

That and the physical and emotionally exhausting nature of the journey itself contributed to their poor psychological condition.

Dr Fitton also says substance abuse-  particularly  among unaccompanied men in transit -  may be seen as self‑medication for hunger, exhaustion and distress.

The drugs, he says, are cheap, widely available along routes, and may even be more accessible than food when resources are scarce.

The researcher interviewed frontline community workers, who explained how recent cuts in international aid to NGOs working in Colombia have intensified gaps in care.

The community workers reported that mental health services for irregular migrants in Nariño are now almost entirely provided by dwindling numbers of humanitarian and community organisations.

As the organisations start to withdraw through lack of funding, irregular migrants are likely to be left with no mental health support at all.

The community workers described how poverty, unstable housing, lack of transport and the pressures of constant movement make it nearly impossible for migrants to seek ongoing mental health treatment.

And there was, said Dr Fitton, confusion among some healthcare staff about migrants’ legal rights and documents conflicting views on whether discrimination affects access to care.

“Our findings show that community workers are doing everything they can, but the system in Colombia is simply not built to meet the mental health needs of people in constant transit,” said Dr Fitton.

“We show a system under strain with community workers struggling to fill widening gaps in support.

“Caught between hunger, exhaustion and exclusion, some migrants slide into a brutal spiral: substances numb pain but deepen isolation, bar them from shelter, fracture their dignity, and leave a mental health crisis untouched.

“What begins as a will to survive has become a sorry tale of abandonment by systems and services.”

• The paper Barriers to access and unmet needs in mental health care for Venezuelan migrants in a southern border region of Colombia: the experiences of community workers is available . DOI:
• Image: John Fitton at the Universidad Cooperativa de Colombia in Pasto, Nariño who hosted him.

Computational simulations of mathematical models of fluid flow are essential for everyday applications ranging from predicting the weather to the assessment of nuclear reactor safety. The advent of this simulation capability over the past 50 year has revolutionised the development of fuel-efficient aeroplanes and sail configurations on racing yachts can now be optimised in real time, providing the marginal gains needed to win races in the Americas Cup.

Optimised aerodynamics means that modern day cyclists can ride faster, golf balls fly further and Olympic swimmers consistently set world records. Computational fluid dynamics also enables the modelling of the flow of blood in the human heart, making the provision of patient-specific surgery possible.

Scientists and engineers rely on computer-based simulations to understand, predict, and design these systems that they can’t easily test in real life. But traditional fluid‑simulation methods often require hours or even days of computation, and struggle when the flow becomes fast or highly complex. 

Machine‑learning‑based simulations, once trained, can make these assessments almost instantly. Instant feedback would allow rapid design testing, real‑time adjustments, and rapid testing variation without the usual computational burden.

The findings were published in the

The study uses the stability of fluid motion as the foundation for a new method that predicts how complex systems behave. Instead of relying on costly laboratory experiments, solutions to the fundamental equations of fluid motion are generated numerically. This allows the machine-learning model to be trained on accurate, high-quality data drawn directly from physics, demonstrating that the model can accurately handle challenging simulations.

A key focus of the work is identifying bifurcation points –the moments when a smooth, steady flow (laminar flow) suddenly begins to change – similar to calm, evenly flowing river as it hits an obstruction, or splits and fluids start to mix and form eddies. Laminar flow is when a liquid behaves in a smooth and orderly way, like pouring honey, the flow is consistent and steady.

By successfully using a machine‑learning model to identify the points at which a system changes behaviour or in this case bifurcates, the study suggests that, with further refinement, machine‑learning‑based models could become a practical alternative to traditional fluid‑modelling techniques in the future.

Professor Silvester added: "This marriage of old and new approaches holds the promise of efficient computation of physically realistic fluid flows in a myriad of practical situations. The development of refined mathematical models of complex fluids is likely to be critically important if the promise of AI is to be effectively realised in the future.”

Delivered by Unit M and enabled by GMCA Investment Zone funding, the will provide each venture with expert commercialisation support, access to mentors, investor readiness training, lab and workspace access, up to £25,000 in equity-free funding, and the opportunity to showcase to investors and strategic partners at a demo day.

The programme supports the University’s vision to become Europe’s most inclusive and impactful innovation ecosystem. The is designed to drive the journey from research to real-world impact, build a strong innovation network, and streamline collaboration, turning ideas into outcomes that benefit society. 

The companies span many different fields, including advanced materials, biotech, space, AI and climate innovation. They include:

• SporeSense – An early disease detection device enabling farmers to identify crop infections before visible symptoms emerge, enabling the reduction, and targeted use, of fungicides. This is being developed by a collaboration of companies and agri-tech specialists, spearheaded by University of Manchester researchers and with commercial development support from the University’s .

• – Imprinted Diagnostics uses a novel form of detection (molecularly imprinted polymers) and a patented detection platform. Commercialisation is being supported by The University of Manchester’s Innovation Factory and is expected to lead to the first product; a rapid, portable, blood test that can diagnose heart attacks on the spot.

• NX Health Limited – The world’s first non-invasive wireless neurostimulation device, a medical technology that delivers targeted, low-voltage electrical currents to nerves or specific brain areas, specifically designed to help individuals with autism spectrum disorder to manage daily challenges that impact their quality of life, such as sensory sensitivities, anxiety and sleep disturbances.

• – Energy-efficient heaters, manufactured in the UK, delivering more than 85% greater efficiency than electric alternatives. WarmTronics actively works in partnership with The University of Manchester.

• Graphene Thermal – Modular floor heating panels that reach operating temperature in under one minute. Using self-regulating graphene nano-composite heating elements, the system delivers instant, on-demand heating, cutting energy use and installation costs versus underfloor heating.

• – This spinout from The University of Manchester Innovation Factory is using advanced materials engineering to increase the length of satellite operations in very low Earth orbit by mitigating atmospheric drag and atomic oxygen erosion. The technology unlocks longer satellite lifetimes, allows for lower orbits, higher-performance Earth observation and better in-orbit communications services.

   

• – Digital solutions that translate complex genomic data into practical guidance for clinicians. The technology integrates these insights directly into clinical systems, supporting safer, more personalised treatment choices.

• – A 3D-omnidirectional wind turbine designed for clean, efficient energy generation in urban settings. This technology unlocks high‑energy wind zones created around buildings, which is up to 27 times stronger, offering major potential for decentralised, resilient urban power.

• Sineco – Real-time data aggregation technology that cleans and integrates biometric signals from wearable devices, transforming noisy, fragmented data into reliable physiological insights. This enables accurate, responsive AI applications that enhance performance, wellbeing, and engagement across fitness, healthcare, and digital environments.

• – A wireless wearable system featuring sensorised insoles and thigh bands that provide real-time feedback to lower-limb amputees. The device is non-invasive, compatible with all prostheses, and delivers multi-point sensory stimulation mapped to different areas of the foot, creating a more intuitive gait experience. Designed for independent use without clinical assistance, it adapts to each user’s needs to support personalised rehabilitation and improved mobility.

, Associate Vice-President for Enterprise and Chief Scientific Officer at Unit M said: “We’re delighted to announce the first cohort of the Unit M . This group reflects the incredible depth of innovation across The University of Manchester and the wider Greater 91ֱ�� ecosystem, bringing together ambitious technical founders with ideas that have the potential to deliver real-world impact. The team are excited to work with this cohort as they take their next steps on their commercialisation journey.”

is open to technical founders and researchers who have moved past early research or initial concept development and already on a path toward turning their science and technology into investment-ready deep tech startups. The programme runs from April – June. This is a multi-year project funded by the GMCA and announcements on future cohorts will be made in the coming months.

Potential investors will have the chance to hear about each of the chosen ventures at a demo day in June and can register to become a mentor.

• on 24 June

The researchers created a new physics-based module that allows heat produced by urban traffic to be represented directly within the Community Earth System Model (CESM) – one of the world’s most widely used global climate models for predicting how the Earth’s climate behaves.

By adding urban traffic-related heat processes directly into the numerical model, the team were able to show how vehicles can measurably raise temperatures in cities and influence how heat moves between roads, buildings and the surrounding air.

The study, published in the , used real-world traffic data, supplied by Transport for Greater 91ֱ�� (TfGM), alongside open datasets to validate the model for 91ֱ��, UK, and Toulouse, France.

Lead author Dr Zhonghua Zheng, Co-Lead for Environmental Data Science & AI at 91ֱ�� Environmental Research Institute (MERI) and Lecturer (Assistant Professor) in Data Science & Environmental Analytics at The University of Manchester, said: “Research on urban heat has traditionally focused on buildings, materials and land surfaces. However, the direct heat produced by vehicles – from engines, exhausts and braking – has received far less attention in large-scale climate models.”

In 91ֱ��, the results showed that traffic heat increased simulated air temperatures by around 0.16°C during summer and 0.35°C in winter. The scientists say that while these temperature increases may appear small, they can make a meaningful difference during extreme heat events.

During the July 2022 UK heatwave, the model suggests that traffic-related heat contributed to increases in human heat stress indicators, pushing the “feels like” temperature above dangerous thresholds for longer periods.

The study also found that traffic heat does not just affect outdoor temperatures, but indoor temperatures too. Heat released at street level can transfer into buildings, increasing the need for air conditioning in summer.

Unlike previous approaches, the new model can also simulate different types of vehicles – including petrol, diesel, hybrid and electric vehicles – and can respond to changes in traffic patterns and weather conditions.

This means scientists and stakeholders can explore how shifts in transport systems, such as the move toward electric vehicles, could change how much heat traffic adds to urban environments.

The work could help cities better understand how transport policy and the transition to cleaner vehicles may influence future climate resilience.

Yuan Sun, first author of this paper and PhD researcher from The University of Manchester, added: “We would like to highlight the importance of considering transport systems when planning for climate adaptation, urban cooling strategies and net-zero transitions.”

Published in Science, the team demonstrated the first atomic‑resolution imaging of atomic behaviour at solid–liquid interfaces in a broad range of non‑aqueous (organic) solvents. Previous high‑resolution liquid imaging techniques were largely limited to water, but the new technique works with a wide range of liquids beyond water, dramatically expanding the range of chemical processes that can be studied at the atomic scale, including key enabling technologies for the green energy transition.

Transmission Electron Microscopy is one of the only techniques that can image individual atoms, using a highly focused electron beam to probe inside structures, but it requires a high vacuum – making it impossible to study liquid processes. The 91ֱ�� team overcame this long‑standing challenge by building “nano‑aquariums”: nanoscale liquid cells made by sealing tiny pockets of test liquids, each just 100 attolitres, a billion times smaller than a raindrop, between ultra‑thin graphene windows just a few atoms thick. The graphene is strong enough to protect the liquid from the vacuum, yet almost completely transparent, allowing the electron beam to pass through.

Using an advanced electron microscope at the electron Physical Science Imaging Centre (ePSIC) national facility, the team captured videos of gold atoms at the graphene–liquid interface to compare five industrial solvents. The resulting videos show individual atoms hopping between sites, pairing up into groups of two and three, and clustering into larger nanoparticles with the measured behaviour sensitive to the choice of liquid. An AI‑enabled automated analysis workflow allowed the researchers to individually “track” more than a million gold atoms across the five solvents, enabling extraction of truly statistically significant information – a far cry from most atomic‑resolution imaging papers, which typically draw conclusions by observing only tens or hundreds of atoms.

“Watching individual atoms move in liquids is incredibly exciting, like having a front‑row seat to chemistry in action,” said Sam Sullivan‑Allsop, postdoctoral researcher at 91ֱ�� and first author. “By tracking more than a million atoms, we can move beyond isolated snapshots and finally see how liquids shape atomic behaviour.”

Our images are clear enough to resolve both the gold atoms and the graphene lattice beneath them,” he added. “That lets us understand not just where the atoms move, but why: how they interact with the surface and why they tend to “pair up” into small clusters during their random motion.”

A key innovation was sealing the cells while fully submerged in liquid using a thin ceramic cantilever to manipulate the graphene crystals. Previous approaches suffered from significant evaporation during the sealing step, causing huge fluctuations in the concentrations of test liquids. The new technique enables precise control of what goes inside – essential for making fair comparisons between liquids.

, who developed the fabrication process, explained, “The trick is sealing the cells while they are submerged within the liquid itself. Doing it this way means you know exactly what sample you are looking at – and it works for nearly every solvent, not just water.”

Individual gold atoms are a promising catalyst for green chemistry but preventing them “clustering” into bigger particles has always been challenging. Using their new platform, the team investigated how both the choice of solvent (which controls dispersion in the liquid) and the drying kinetics (which lock in the final structure) together determine whether the final catalyst contains the individually separated gold atoms required for high performance. In particular, acetone – a common solvent – combined low polarity with a low boiling point and surface tension, helping gold atoms remain separated during both the liquid phase and drying, whereas higher‑boiling solvents (e.g., cyclohexanone) and water tended to yield larger particles. The structural findings were confirmed by catalyst testing by collaborators at the University of Cardiff’s Catalysis Institute.

However, the new technique has potential for significant impact in fields outside catalysis. Many crucial processes, from fuel cells and batteries to filtration and precious‑metal recovery from e‑waste, happen at solid–liquid interfaces. Until now, scientists mostly relied on ensemble measurements that can obscure atomic‑scale complexity; watching individual atoms in liquids changes that.

, who led the research, commented, "It's remarkable how much we still don't understand about how atoms behave at solid‑liquid interfaces, given how fundamental these processes are to modern technology. Now we can watch what's actually happening, understand why, and use that insight to design better materials and processes."

The research involved collaboration between The University of Manchester, Cardiff University, Sheffield University, and the ePSIC national microscopy facility at Diamond, combining expertise in electron microscopy, 2D materials fabrication, catalysis, and computational modelling. With the platform now established, the team is already applying it to questions in clean energy technologies and recovery of metals from e‑waste.

This research was published in the journal Science.

Full title: Atomic-resolution imaging of gold species at organic liquid-solid interfaces.

DOI:

The new grant funded by an Engineering and Physical Sciences Research Council (EPSRC) Health Technologies Connectivity Award will assess the benefit and suitability of the software for use within the NHS.

The researchers hope the software, called (In Silico Assessment of pregnancy via Digital Integrated Environments) will help doctors tackle the stubbornly high prevalence of stillbirths. Late-term losses are especially hard to foresee, as clinicians continue to lack an accurate means of assessing a baby's oxygen supply before birth.

Around half of stillbirths are associated with fetal growth restriction (FGR), a condition caused by impaired placental function that limits the baby’s growth. Current ultrasound tools detect only around half of FGR cases, and even when identified, there is no treatment. Clinicians must instead make complex decisions about the timing of birth, balancing the risks of premature delivery against the danger of waiting too long.

from The University of Manchester said: “Today’s clinical decision-making relies on indirect indicators such as Doppler ultrasound, fetal movements and heart rate patterns. While umbilical artery Doppler has helped reduce stillbirth risk in premature babies, most stillbirths still occur in pregnancies where Doppler results appear normal. Crucially, no existing clinical test can directly assess fetal oxygenation – the primary driver of stillbirth risk.”

Dr Michele Darrow from the Rosalind Franklin Institute said: “By integrating computational physics-based modelling, imaging science and physiological insights, the software we have developed is able to generate real-time, actionable information.”

The researchers are working with international partners at the University of Auckland to address the gap by rethinking how routinely collected clinical data are interpreted. The Auckland team’s work focuses on integrating physiological understanding with advanced physics-based modelling. This approach underpins the development of SADIE, which uses existing ultrasound technology and clinical data to predict fetal oxygen status in under 30 seconds. 

Dr Darrow added: “While the proof-of-principle results are promising, further work is needed before SADIE can be tested in large‑scale clinical trials. This new funding aims to ensure the models can run reliably in real time and produce predictions that clinicians can rely on.”

Working with clinicians and health system leaders, the team will also assess where SADIE will fit within current NHS care pathways. This step is essential to designing future clinical trials that can demonstrate whether smarter use of ultrasound data can reduce stillbirth while avoiding unnecessary early intervention.

By combining imaging science, computational modelling and clinical insight, this work reflects the researcher’s mission to develop transformative technologies that improve human health.

The event, Powering Research Commercialisation Across the North, hosted by the Innovate UK ICURe in partnership with The University of Manchester and NxNW Partners, marked a significant moment for the UK’s innovation ecosystem. It brought together key stakeholders to launch the new Innovate UK ICURe strategy, which sets out a renewed focus on strengthening research commercialisation across the UK, aligning with the UK Government’s priority industrial sectors, supported by a coordinated regional delivery.

Innovate UK’s Innovation-to-Commercialisation of University Research (ICURe) programme is the UK’s flagship early-stage research pre-accelerator. Through closer collaboration between regional partners, ICURe aims to support a stronger pipeline of investment-ready opportunities and deepen connections between research, industry and investors.

The programme will be delivered through the North by Northwest (NxNW) consortium – a partnership of universities across the North of England, Scotland and Northern Ireland. The University of Manchester will lead the NxNW consortium through the University’s gateway to innovation.

Professor Aline Miller, University of Manchester and Unit M, said: “NxNW Partners, University of Manchester and Unit M all share a strategic vision; to strengthen the innovation ecosystem across the northern belt of the UK. We see ICURe as central to our plan and an enabler of commercialisation of cutting-edge research across the priority sectors of the UK Industrial Strategy.

“It was clear from the event that the UK’s ability to scale research-driven innovation depends on stronger connections between regions, partners and investors. We’re working in collaboration with our regional partners to build the conditions for research-led companies to start, stay, grow and scale.”

During the event, spin-out showcases and networking sessions provided a platform for emerging ventures to engage directly with investors and partners, reinforcing the strength of the pipeline being developed through ICURe.

Partners attending the launch included representatives from UKRI, Greater 91ֱ�� Combined Authority (GMCA), Liverpool City Region (LCR), Northern Gritstone, Invest Northern Ireland, Scottish Enterprise, and university partners from across the NxNW consortium.

Since its launch in 2014, Innovate UK ICURe has played a pivotal role in supporting researchers to translate early-stage technologies into commercial opportunities. The programme has supported the creation of 388 spin-outs, helped ventures raise £1.61 billion in additional investment, and contributed to the creation of 2,495 jobs. Today, 32% of ICURe teams are female-led, reflecting a continued commitment to broadening participation in innovation.

By combining funding, customer discovery and commercial expertise, ICURe acts as a critical pipeline for research-driven innovation and a key enabler of regional innovation ecosystems.

Professor Aline Miller added: “The ICURe NxNW event underscored the growing strength of the North as a connected and collaborative innovation ecosystem. With strengthened regional leadership, aligned national delivery and a clear focus on supporting ventures from early-stage research through to scale, ICURe is playing a central role in shaping the future of UK research commercialisation.

“As the programme enters this next phase, its continued success will depend on deepening partnerships, strengthening investment pathways and ensuring that the UK’s most promising technologies are supported to reach their full potential.

“Together, we’re building a more connected, impactful future for UK research.”

Geeta Nathan, Deputy Director of Innovation Ecosystems at Innovate UK, said: “Bringing together the ICURe and NxNW community in 91ֱ�� highlighted both the strength of the UK’s research base and the scale of opportunity ahead. Our focus is on backing bold ideas aligned to the UK’s priority industrial sectors (IS-6), with real commercial potential, supporting strong teams and creating clearer pathways from research into market.

"The launch of the next phase of Innovate UK ICURe, alongside initiatives such as the UKRI Venture Builder pilot, reflects our commitment to strengthening those pathways and helping early-stage ventures build momentum. By working closely with our delivery partners and regional ecosystems, we are creating the conditions for more research-driven businesses to start, grow and scale across the UK.”

Published in the journal , the study shows that SAFER‑Dem is highly inclusive and has the potential to provide safer, more coordinated transitions from hospital to community care, which supports the goals of the NHS 10‑Year Health Plan for England.

The study is funded by the National Institute for Health and Care Research (NIHR) Three Schools Dementia Career Development Award and the .

Care bundles are a set of practical, evidence‑based interventions designed to improve the quality and safety of care for patients. The NHS Improvement SAFER patient flow bundle, for example, is a practical tool designed to reduce delays and improve patient safety in adult inpatient wards. The research team had already developed a care bundle called SAFER‑Mental Health (SAFER‑MH), which is an adapted version of the NHS SAFER patient flow bundle tailored to the specific needs of mental health settings.

By applying a co-designing approach, researchers worked with participants to redesign SAFER‑MH into a clearer, simpler, and more dementia‑inclusive version, the SAFER-Dem.  

, Research Fellow at the University of Manchester, who led the study, said: “People with dementia often have difficult experiences when discharged from mental health hospitals. Many feel confused, unheard, or not involved in decisions about their own care. Staff also report challenges, such as lack of time, unclear communication and busy ward environments.

“We worked directly with people living with dementia, unpaid carers, and healthcare professionals to help improve the discharge process from hospital to community for people with dementia. Our study participants took part in workshops and interviews, where they tried out early versions of the SAFER‑Dem materials and gave feedback. Altogether, 29 people participated.”

Participants agreed that current discharge processes are often poor. Common problems included unclear communication, not receiving enough information, difficulty navigating busy environments, and a lack of involvement in planning. Medication information was a particular concern. As a result of the workshops and interviews, key changes were proposed to refine the dementia-inclusive discharge care bundle.

Overall, participants felt that SAFER-Dem could help improve conversations, support shared decision‑making, and make the discharge process feel more person‑centred. However, they noted that people with more severe dementia may need more support or may not always be able to use the materials independently.

Co-author Professor Maria Panagioti from The University of Manchester said: “Our study shows that by improving the quality and consistency of discharge planning, SAFER-Dem has the potential to enhance patient safety, strengthen system resilience, and support more timely discharges where appropriate. It may also help reduce avoidable readmissions by ensuring that patients leave hospital with the right support in place.

“The SAFER-Dem intervention is not just about speeding up discharge, but about improving how discharge is delivered—making it safer, more personalised, and more effective for both patients and the wider health system.”

The researchers concluded that SAFER‑Dem shows real promise for making discharge from mental health inpatient care safer, clearer, and more inclusive for people living with dementia. Further evaluation and testing will help determine how SAFER‑Dem can be scaled across mental health services.

• The paper SAFER-Dem: generating co-designed adaptations to a discharge care planning bundle for people living with dementia, published in the BMJ Open is available . DOI: 

DOI:  

Professor Zara Hodgson FREng is an internationally recognised expert in nuclear energy policy and research, and Director of the University’s Dalton Nuclear Institute. She has been appointed to support the NDA 2026 Review, which has been commissioned by the Government to provide assurance on the NDA’s performance and governance, and to make recommendations on improvements.

The Review is led by Dr Tim Stone CBE, a senior expert adviser to five previous Secretaries of State in two successive UK governments and the Chair of Nuclear Risk Insurers. Professor Hodgson will join a team of three other independent experts to support Dr Stone.

The review will focus on the NDA’s strategic planning and management, project and programme delivery, and financial management. It will assess how effectively the NDA delivers value for money for the taxpayer while maintaining the highest standards of safety, transparency and governance across the UK’s civil nuclear legacy. Reviewers will challenge current practices, propose bold value-for-money recommendations, and highlight good practice while identifying areas for improvement.

Professor Hodgson is a Professor of Nuclear Engineering at The University of Manchester and has played a pivotal role in recent UK Government interventions to grow the UK’s nuclear fuel production capability. Her work has supported the UK’s Net Zero ambitions, strengthened energy security and helped build more resilient nuclear supply chains. At 91ֱ��, she leads contributions to national nuclear programmes through high impact research, education and training, and independent advice.

Professor Hodgson’s appointment reflects The University of Manchester’s leadership in nuclear research and policy, and its long-standing role in providing independent expertise to inform national decision-making.

The striking structure located within the leafy Brunswick park area of campus is being modernised to ensure students will have the best experience while studying at 91ֱ��. 

“The Zochonis building is being comprehensively refurbished to become one of the first net zero carbon buildings on campus. The refurbishment delivers modern lecture theatres and teaching rooms, dedicated research facilities for clinical, developmental and experimental psychology, and welcoming student social and study areas, all designed to support learning, collaboration, and wellbeing.”  Dr Nils Muhlert, Head of Division for Psychology, Communication & Human Neurosciences, Academic Lead for Zochonis refurbishment.

Students will enjoy:

• Refreshed teaching spaces and lecture theatres
• A cozy campus hub where you can prepare lunches and relax
• Modern study spaces
• State-of-the-art psychological research spaces, including clinical suites and virtual reality facilities.   

Zero Carbon
The Zochonis refurb project is a big step towards UoM’s carbon reduction ambitions. Matt Ellmore, Senior Project Manager, Estates & Facilities Directorate said:  “We are insulating the roof and facade, servicing all windows, switching to LED lighting throughout, installing solar panels, and replacing the gas boiler system with air-source heat pumps. These measures will result in an 80% annual reduction in emissions, equivalent to 238 tonnes of carbon saved each year.” 

Delivering sustainability
In addition to improving carbon and energy efficiencies, the university is also aiming to enhance students' experience by increasing the quality of cycling facilities, connecting researchers to data from projects, sharing innovations and best practice with our partners and supplying a healthy environment that provides for people and nature.  

One object that caught the eye of researchers at The University of Manchester was a simple drinks can. When crushed while filled with liquid, it behaves completely differently from an empty one. Instead of collapsing suddenly, it produces an ordered sequence of circular rings that appear one by one.

But it turns out there’s more going on than just a satisfying visual. Published in the journal , the 91ֱ�� team has discovered that the formation of corrugations follows a rare mathematical process - and the discovery could have implications for safety across multiple industries.

Lead researcher, , PhD researcher at The University of Manchester, said: “Most of us have stamped on an empty can and watched it collapse instantly. But a full can behaves completely differently. It forms one buckle after another in an orderly fashion, until the whole can is wrapped in evenly spaced corrugations. We were fascinated and wanted to understand what was driving that behaviour – particularly as liquid-filled containers are found everywhere in our day-to-day lives.”

To find out, the researchers combined laboratory experiments with a type of mathematical modelling typically used to study natural pattern formation, such as water ripples or wave formations.

They discovered that the sequence of buckles is anything but random. Because the liquid inside the can is almost incompressible, it changes the way the aluminium can carries force.

“A standard can usually starts to buckle near the middle,” explained , Reader in Nonlinear Dynamics at The University of Manchester. “But tiny variations in shape or size of the can, can shift where the first ring appears. After that, however, the physics takes over, and the sequence becomes extremely predictable. As the can compresses, the metal softens and then stiffens again – this cycle naturally forms the rings. Even changes in the can’s internal pressure don’t alter the overall pattern much. That tells us that the buckling sequence is a fundamental property of any liquid-filled cylinder made from metal, not just a quirky effect of a drinks can.”

The team discovered that this step-by-step pattern matches a mathematical process known as homoclinic snaking - a phenomenon where bumps or ripples appear one by one in a precise, controlled order. Although mathematicians have suggested that this ‘snaking’ could underpin the buckling of cylinders, uncovering its trace in a real physical system is exceptionally rare.

The findings could also have far broader implications. Liquid-filled metal cylindrical shells are used throughout modern engineering — in industrial storage, transportation, construction, energy systems, and even in parts of rockets.

Yet, despite their ubiquity, engineers have lacked a clear understanding of how these structures might buckle when compressed.

, Royal Society University Research Fellow at The University of Manchester. said: “Understanding the exact sequence of buckles could help engineers spot the early warning signs of failure long before a system collapses. That could lead to safer designs, better monitoring techniques, and more reliable structures in a whole range of industries. It might even open up possibilities for manufacturing. For example, it could be possible to create corrugated cans after filling without needing a mould.”

During an emotional visit to The Christie NHS Foundation Trust in 91ֱ�� and the 91ֱ�� Cancer Research Centre, Kimberley met with scientists and researchers and witnessed first-hand how The Christie Charity Sarah Harding Breast Cancer Appeal, set up at Sarah’s request and supported by the bandmates, is transforming lives.

At the heart of that impact is Annette Illing, a mum of three who had no symptoms, no family history of breast cancer, and no reason to suspect anything was wrong. But after taking part in a groundbreaking study to identify which women are most at risk of developing breast cancer in their 30s and backed by the Appeal, Annette received news that would change everything.

What began as a simple decision — “Why not?” — led to an early diagnosis that may ultimately have saved her life.

Annette’s dad and sister are both GPs, and the opportunity to better understand her breast cancer risk while contributing to vital research felt like a positive step. “I couldn’t really see any negatives,” she recalls. “It would either be ‘I’m fine’ and carry on as I am, or ‘I’m at increased risk’ and might need to make some lifestyle changes.”

At just 39 years old, and with no family history of breast cancer, Annette wasn’t overly concerned about having a genetic risk factor.

After researching the (Breast Cancer Risk Assessment in Young Women) study and learning it was supported by The Christie Charity Sarah Harding Breast Cancer Appeal, () Annette decided to take part. The BCAN-RAY study is also funded by Cancer Research UK with support from the Shine Bright Foundation.

It was a decision that proved life-changing as in June 2025, after Annette had been identified as being at increased risk by the BCAN-RAY study, she had her first mammogram and was diagnosed with early-stage breast cancer.

She says: “It was a huge shock as I don’t have a family history of breast cancer. It was scary to hear the word ‘cancer,’ but there was hope. I’d rather know and have choices than not know. It was caught early, meaning it could be removed, and preventive treatment was available.”

Without the BCAN-RAY study, Annette would have waited another decade for her first routine mammogram. “When the mammogram picked up my cancer, it was undetectable by any other means. If I’d waited, it would have grown and changed my prognosis. It could have been a completely different story,” she says.

Dr from The University of Manchester, The Christie NHS Foundation Trust and 91ֱ�� University NHS Foundation Trust (MFT), leads the BCAN-RAY study and said: “This study was designed to identify women at increased risk of breast cancer. Annette’s experience shows exactly why this is so important. By detecting breast cancers at the very earliest stages, treatment is more straight forward and survival outcomes much better. We can also offer women approaches to prevent breast cancer to stop them developing the disease at all. Early detection may have saved Annette’s life, and we want to offer that same chance to many more women.”

Annette from Withington, 91ֱ��, underwent two surgeries at Wythenshawe Hospital, part of Manchester University NHS Foundation Trust, followed by radiotherapy at The Christie NHS Foundation Trust, and is now on preventive hormone therapy for five years. She will also have annual mammograms for peace of mind. She says: “I feel very hopeful for the future. My cancer has been removed, and I’m in the best possible position to move forward.”

As a mum to three daughters aged 13, 11 and 8 yrs old, Annette is particularly thankful to have been part of the BCAN-RAY study. She says: “I am so grateful for this study and future studies like it, so that I know my daughters will be well looked after by the Breast Cancer Family History Risk and Prevention Clinic when the time comes.”

She adds: “I could not have got through the last six months without the support of my husband Mark, my daughters and my faith. To my family and friends who have picked me up when needed, listened to me and allowed me an outlet to process each step; to my group of ladies who I met during surgery and physio  sessions, who I have shared experiences with and understand what it's like to go through the treatment; to my employer and class team who have been incredibly supportive, I thank each and every one of them.”

Annette now encourages others to take part in studies like BCAN-RAY and to perform regular breast checks. “Many women I’ve met found their cancers by noticing changes. Please check your breasts regularly,” she says.

Dr Dani Skirrow, Science Engagement Manager at Cancer Research UK, said: “Even in the darkest days of her cancer journey, Sarah Harding was a fearless advocate for research. She bravely faced up to the pain the cancer caused her, undergoing treatment whilst thinking of ways to help other women in a similar position.

“It is a fitting tribute to Sarah that the study supported by her legacy has taken us towards smarter ways to identify women who have a high risk of getting breast cancer when they’re young. We’re getting promising insights into how we could provide tailored support to these women in their thirties, offering them access to early screening and prevention opportunities. Annette’s story illustrates the powerful impact this could have in the future.

“Further research will be needed to refine the tools created as part of this study before they can be rolled out more widely. But the progress made by the BCAN-RAY study moves us closer to a world where people can live longer, better lives, free from the fear of breast cancer.”

Research such as the BCAN-RAY study is central to The Christie Charity's commitment to supporting The Christie hospital’s vision of ‘learning from every patient’ and trebling the number of patients participating in research by 2030. Studies have shown that cancer patients treated at research-intensive hospitals have better outcomes than those treated in hospitals with little or no research activity. The Charity has pledged to support and fund this goal with £30m over the next five years to accelerate research and innovation in 91ֱ��, with the ultimate aim of bringing tomorrow’s treatments to patients faster.

• Find out how you can support innovative cancer research at The University of Manchester here: Challenge Accepted
• Picture caption: Kimberley with members of the BCAN-RAY research team

Building more reliable AI molecular models

Machine‑learned potentials (MLPs) are widely used to approximate quantum mechanical behaviour in molecules, but most existing models become unstable when molecules experience heat, movement or structural distortion. This makes long, reliable simulations extremely difficult to achieve.

The 91ֱ�� team – Bienfait Kabuyaya Isamura, Olivia Aten, Mohamadhosein Nosratjoo and – has solved this long‑standing challenge by integrating deep physical knowledge directly into their model. 

The researchers built a new AI model using Gaussian process regression, to understand how atoms in a molecule naturally behave. To do this, they fed the model detailed information about how atoms interact in real life, based on the rules of quantum physics, to help the AI make more realistic predictions about how each part of a molecule should move.

They also discovered that a small mathematical choice, called the “prior mean function”, affected the stability of the model; with this function in place, the AI had the correct “starting point” to create and sustain a stable model even when a molecule is stretched, heated or shaken.

A smarter way to keep molecules from breaking down

Unlike conventional approaches, the new model uses real-world physical principles to prevent atoms from collapsing together or flying apart when the molecule enters high‑energy states. This enables reliable simulations even far beyond room temperature.

The team demonstrated the model’s robustness with 50 independent simulations, each lasting 10 nanoseconds, totalling 0.5 microseconds of stable dynamics, a milestone rarely achieved by machine‑learning force fields. Even highly flexible molecules such as aspirin, serine and glycine remained stable throughout.

The model was also able to repair distorted structures and accurately reproduce known conformations, such as those of alanine dipeptide, a key benchmark molecule in computational chemistry.

Beyond stability, the model is computationally efficient, running on standard CPU hardware at speeds comparable to or faster than leading neural‑network-based potentials that require high‑end GPUs.

The research opens up new opportunities for simulations in extreme environments, condensed matter and biomolecular systems where long‑timescale accuracy is essential. The team is now extending the approach to include electron correlation effects and develop more transferable descriptors.

Ava Begley’s parents say they feel “deeply grateful” that the researchers, from 91ֱ�� University NHS Foundation Trust (MFT) and The University of Manchester (UoM), have made this discovery, which is one of the most common genetic causes of severe epilepsy.

Delivered through the this groundbreaking work is already transforming the lives for many children and young people around the world, providing long-awaited answers and hope for the future.

Ava’s parents, Daniel Begley and Elizabeth Dowd, from Sydney, Australia, said: “Our first reaction was a mixture of emotion – relief at finally having a diagnosis, but also sadness in understanding the seriousness of the condition and how rare it is. Above all, we felt grateful that Ava’s experience may contribute to greater knowledge and future progress and treatment.”

This new condition, which the researchers have named as “Recessive RNU2-2-related neurodevelopmental disorder”, results in difficult-to-control seizures and severe developmental delays in children, often appearing within their first year of life.

Published in the journal , the research has so far identified 84 individuals living with the new condition, while experts estimate that thousands more remain undiagnosed across the world.

The team estimates that millions of people globally could be ‘carriers’ of the faulty gene behind this disorder.

91ֱ�� lead and first author of the paper Dr Adam Jackson, Academic Clinical Fellow at the 91ֱ�� Centre for Genomic Medicine, part of MFT, and The University of Manchester, explained: “We believe that as many as in 1 in 100 people could unknowingly be carriers of this condition. If both parents are carriers, there is a 1 in 4 chance with every pregnancy that their child could be affected. We estimate roughly 1 in 40,000 people may be living with this condition, making it one of the most common neurodevelopmental disorders currently known. Our discovery brings hope for many patients and families who have been searching for answers and is already having a positive impact around the world.”

This major advance builds on in which they showed the importance of the RNU genes in brain development and function.

The research team made the new discovery by analysing changes in several hundred RNU genes in data of individuals who took part in the 100,000 Genomes Project, a Genomics England initiative to sequence and study the role genes play in health and disease.

Dr Jackson, who is also an early career researcher in the NIHR 91ֱ�� BRC’s Rare Conditions Theme, explained: “What makes this discovery even more remarkable is that RNU2-2 is extremely small in comparison to other genes. Unlike most other genes, RNU2-2 does not even make a protein. We were astonished to discover how changes in this tiny gene can have such profound effects in so many individuals.”

Children with the condition experience severe early on in life, often in their first year. This means they have seizures – sudden surges of electrical activity in the brain which can cause the body to stiffen, jerk, shake and lose consciousness. These seizures can be difficult to fully control with medication, highlighting the urgent need for improved therapies.

The condition also has a profound impact on brain development, causing delays or inability to achieve key milestones such as walking or talking. Almost all affected individuals have significant learning problems.

Ava’s story

6-year-old Ava has lived with complex neurological symptoms from early childhood and requires full-time care and ongoing medical support.

Ava’s condition includes developmental delay, profound intellectual disability and severe epilepsy with frequent seizures. She would often experience 100 to 200 seizures per day, but these are now more controlled with medication.

Ava is non-verbal and cannot communicate through speech or gestures. She requires full-time support with daily life, including bathing, toileting and feeding. She also experiences major motor and balance difficulties, can only walk short distances and falls frequently. Ava often bites and pulls hair out and screams in frustration.

Collaborating with 91ֱ�� researchers, the Sydney Children’s Hospital Clinical Genetics Team who support Ava and her family, were able to link Ava’s condition to the newly identified recessive RNU2-2-related disorder.

Ava’s dad, Daniel and mum, Elizabeth, said: “Ava is a beautiful little girl with a bright presence. She loves looking through books, music, sensory play, being outdoors, and spending time with her family. Even with the immense challenges she faces, Ava brings extraordinary love and meaning into our lives. She has a deep presence about her that touches everyone who meets her.

“For many years we have been through extensive medical investigations, specialist appointments, and genetic testing, hoping to find an answer that could explain Ava’s condition and guide her care. Like many rare disease families, we have lived with a long period of uncertainty.

“Having a diagnosis is incredibly meaningful. It gives Ava a name and a place in the medical world, rather than being an unanswered mystery. It helps us feel that we are getting closer to the starting point of being able to find a cure/treatment, and provides hope that research and awareness may lead to better understanding and support in the future.

“We believe that rare disease research is vital, not only for families like ours, but for the broader medical community. Ava’s journey has been challenging, but she is deeply loved, and we are committed to advocating for her and for all children living with rare and complex conditions.”

91ֱ�� lead and senior author Consultant Clinical Geneticist at the 91ֱ�� Centre for Genomic Medicine at MFT, Professor of Genomic Medicine and Rare Diseases at UoM and Rare Conditions Theme Co-Lead at the NIHR 91ֱ�� BRC said: “Our work helps expand knowledge of conditions related to RNU genes, an emerging group of diseases which potentially affect around 1 in 10,000 individuals globally. It also shines a light on the regions of the human genome sometimes dismissed as ‘junk DNA’. We now see that so-called ‘dark regions’ are vital for health.”

Prof Banka, who is also Clinical Director of the , a virtual centre based at MFT which aims to improve the lives of people with rare conditions, added: “At MFT, we have established a dedicated RNU clinic to identify and support more patients with these conditions. Looking to the future, this discovery paves the way to help unlock life-changing treatments for the recessive RNU2-2-related neurodevelopmental disorder.”

Professor Marian Knight, Scientific Director for NIHR Infrastructure, said: “Discovering the cause for conditions like Ava’s is the first step to personalised treatment and improved lifelong health and quality of life. This breakthrough is a testament to the robust research infrastructure the NIHR has developed over the last 20 years, enabling us to turn world-class genomic science into better care.”

• The paper 'Biallelic variants in RNU2-2 cause a remarkably frequent developmental and epileptic encephalopathy is published in DOI: . 

A team of cancer genomics* scientists from The University of Manchester and The Institute of Cancer Research, London, forensically examined the genetic make-up of tumours in 16 different cancers. Their findings, which have been published in , are the culmination of six years’ of research and could significantly increase the number of cancer patients eligible for targeted and immune-based treatments. 

This landmark study was co-led by Professor David Wedge at the 91ֱ�� Cancer Research Centre and Professor Richard Houlson from The Institute of Cancer Research. It used whole-genome sequencing data from nearly 11,000 NHS patients with cancer, and is part of Genomics England’s 100,000 Genomes Project, which is the largest single genomics study for cancer ever to be undertaken worldwide. 

The researchers analysed hundreds of millions of mutations in 11,000 tumours which covered the whole genome of a human being which consists of more than three billion bases and includes around 20,000 genes. From this they were able to identify the most comprehensive map to date of genetics ‘scars’ left behind in cancer DNA. 

In total the team of ‘data detectives’ catalogued 370 million mutations and assigned them to 134 distinct mutational ‘signatures’ which are patterns of DNA damage that act like fingerprints of the processes that caused the cancer. Of these, 26 signatures were not previously included in the database of known signatures used by many scientists. 

The most significant finding was that many more patients may benefit from precision therapies than currently recognised. The study identified large numbers of tumours with evidence of homologous recombination deficiency (HRD) which is a weakness in DNA repair that makes cancers vulnerable to PARP inhibitors and platinum-based chemotherapy. HRD was identified in 16% of breast cancer tumours and 14% of ovarian cancer tumours, so based on UK figures, researchers estimated that more than 7,700 breast cancer patients and over 1,000 ovarian cancer patients in the UK could benefit from HRD-targeted therapies which is much greater than are currently identified through standard genetic testing for mutations in genes such as BRCA1/BRCA2 alone. 

This study also supports the growing theory that toxins produced by particular strains of E. coli in the gut could be the potential cause of the rise in early-onset bowel cancer in younger people. The team found this signature occurs more in younger patients than older patients, in contrast with several other signatures that tend to increase with a patient’s age. 

, professor of cancer genomics and data science at The University of Manchester said: “Every cancer develops because DNA is damaged over time. Different causes such as ultraviolet light, tobacco smoke or inherited gene faults leave different patterns in the genome. By reading these patterns we can now understand, in a larger proportion of cancers, what caused the cancer, when key mutations occurred, and which treatments are most likely to work.

“Until now, most testing has focused on mutations of a single base (or ‘letter’) in a cancer’s DNA. By analysing the entire genome and examining more complex mutations that affect multiple bases, I hope our research contributes to better predictions of which treatment might benefit specific patients. This could enable better targeting of treatment to those patients most likely to benefit, given the genetic make-up of their tumours.”

Professor Richard Houlston, head of cancer genomics at The Institute of Cancer Research, London, said: “The scale of this study was very large, as we analysed samples from almost every tumour type. The quantity of data was enormous, and although laborious to work through, we have been rewarded with a very exciting outcome. This study provides one of the clearest demonstrations yet that reading the full genetic history of a tumour can unlock clues to better patient care.  The future of cancer treatment lies not just in finding mutations, but in understanding the story they tell.”

Professor , Director of the 91ֱ�� Cancer Research Centre, a partnership formed in 2006 by The University of Manchester, Cancer Research UK and The Christie NHS Foundation Trust said: “This remarkable and comprehensive study demonstrates how 91ֱ�� is leading the charge in the field of big data genomics. The world-class research coming out of the Wedge lab is pioneering, and will transform our understanding of the human genome and the potential for better cancer treatments for our patients.”

The study is supported by the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre. 

* cancer genomics is the study of genetic changes in cancer cells to understand tumour development, progression and to guide personalised treatment.

• The study a Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types is published in https://doi.org/10.1038/s41588-025-02474-x

Building on existing collaboration, the partnership aims to address both immediate and longer-term challenges across the water industry, including climate resilience, water quality, wastewater management and resource optimisation.  

The partnership comes at an important time for the sector, as it undergoes rapid transformation in response to climate change, population growth, and an evolving policy and regulatory environment. The University will support this challenge by providing research-driven solutions that support water quantity and quality for communities and the environment.

Under the MoU, the University and United Utilities will expand engagement across strategic innovation priorities, aligning academic expertise with company needs and opportunities, to deliver tangible, real-world impact.

On a visit to the University, the group toured the robotics lab based in the University’s flagship engineering building, observing some of the cutting-edge robotics equipment that is being developed for real-world applications.

Recent collaborative projects between the two organisations include the use of robotics for water network inspection, and a digital twin for the GMCA Integrated Water Management Plan.

Sarah Sharples, Vice President and Dean of the Faculty of Science and Engineering, said: "This partnership marks an important step in uniting academic excellence with industry expertise to address the evolving challenges of the water sector. Together, we aim to drive innovation opportunities that benefit students, research, and society."

Dr Louise Bates, Director of Business Engagement and Knowledge Exchange at The University of Manchester, said: “Collaboration between The University of Manchester and United Utilities dates back to 2006, and in recent years it has really grown through joint research and student-focused activities. This has created a strong foundation for us to build on through this new Memorandum of Understanding.” 

Jo Harrison, Director of Asset Management at United Utilities, said: “We are passionate about securing resilient services for the North West, both now and for the future.

"This partnership builds on a strong foundation of collaboration and gives us an exciting opportunity to bring together world-class academic insight with practical, real-world experience. By combining our strengths, we can make a meaningful and lasting difference on the ground, helping to deliver a stronger, greener and healthier North West for generations to come.”

Solving mechanistic models of natural environments is notoriously time‑consuming and often unstable under diverse real‑world conditions. To overcome this, the team trained AI “emulators” to reproduce the behaviour of an existing mechanistic model that describes carbon cycling in ocean sediments. Once trained, these emulators could then be applied globally to predict dissolved organic carbon behaviour at a resolution and scale that were not feasible using the original numerical model alone.

The study reveals that 11% of the particulate organic carbon arriving at the seafloor is returned to seawater as dissolved organic carbon, while 24% is sorbed onto minerals. Strikingly, about half of all solid‑phase organic carbon in the upper metre of marine sediments appears to originate from dissolved carbon that has been sorbed onto minerals. These findings provide the first global quantification of dissolved organic carbon cycling within sediments and highlight its significance within Earth’s long‑term carbon budget.

In developing the modelling framework, the researchers compared deep learning architectures, random forest models and simpler feedforward artificial neural networks. Unexpectedly, the simplest algorithms produced the most accurate predictions. The team confirmed these results by validating emulator outputs against low‑resolution global maps, where the mechanistic model remained numerically solvable, as well as against algebraic solutions for variables with known analytic expressions. They also found that increasing the complexity of the neural network structures consistently reduced prediction accuracy, offering rare empirical support for the Principle of Parsimony, also known as Occam’s Razor, within AI model development.

These insights have important implications for climate science. Quantifying carbon budgets across the sediment–water interface is essential for understanding global climate dynamics but has historically been hindered by computational limitations. By providing a fast, scalable and accurate way to represent sediment carbon processes, the new AI‑based framework can be integrated into global circulation models and used to explore potential ocean‑based climate change mitigation strategies. The research opens new avenues for simulating and testing how marine carbon reservoirs may respond to environmental change in the coming decades.

Read further papers related to this research:

• Preservation of organic carbon in marine sediments sustained by sorption and transformation processes
  DOI:
• Potential use of engineered nanoparticles in ocean fertilization for large-scale atmospheric carbon dioxide removal
  DOI:
• Long-term organic carbon preservation enhanced by iron and manganese
  DOI:

Sending waste to landfill generally produces the highest levels of net greenhouse gas emissions of any waste treatment option. While it’s a common belief that anything placed in a ‘black bag’ or general waste bin ends up in landfill, this isn’t always the case; landfill plays a much smaller role in the UK waste industry than it used to – and has been eliminated on campus in relation to the University’s two main waste contracts.

Instead of landfill, the University’s non-recyclable general waste now goes through a process known as Energy from Waste (EfW), a waste management method that converts non-recyclables into electricity and heat. Once waste is collected on campus, it is transported to a waste transfer station nearby, where it is ‘bulked up’ before being sent to an EfW facility.

At the EfW facility, it is burned under safe and controlled conditions. The process of burning the waste generates heat, which is then used to power steam turbines and produce electricity, ensuring that every by-product (which includes ash and metals) is recovered and reused, meaning nothing goes to landfill.

The University will remain committed to creating a sustainable campus, by looking at reducing waste to keep products, parts, and materials in use for as long as possible, to strengthen its circular economy.

Sarah Choi, Environmental Sustainability Manager, said: "Achieving Zero Landfill shows what's possible when we work together to align our processes with our sustainability goals. It's a huge step in our environmental ambitions and strengthens our commitment to create a more circular, responsible campus."

The University has a commitment to be zero carbon by 2038, and last year began powering its campus with clean, renewable electricity from a major new solar farm. The University ended all investments in fossil fuels in 2022.

To find out more about this and other commitments around waste, transport and nature, visit the Sustainability website.

The Connect & Contribute Mentoring Scheme matches students studying on one of the University of Manchester’s Education programmes with teenagers who are thinking of applying to university but are unsure of whether higher education is for them. Under the scheme Year 12 students at Cheadle Hulme, Didsbury and Trinity High Schools have been matched with university students, most of whom are in their early 20s and many of whom are from overseas. 

Dr Rui He, Senior Lecturer in Education and Dr Alex Baratta, Reader in Language and Education at the University of Manchester have helped to set up the scheme. Dr He explains: 

“Connect & Contribute matches local sixth form pupils who are in the first year of studying for their A Levels with students who are already in higher education.  

“The scheme allows young people who are considering applying for university, but may be the first person in their family to do so, to connect with someone who is currently attending university. Many of our students have travelled to the UK to continue their postgraduate qualification having already completed a degree in their home country, so can also give information and reassurance about moving away from home. 

“We’ve found that by offering young people the opportunity to have structured but informal conversations with someone who is fairly close to them in age we can build their confidence in applying to university. We can also provide practical information on the sort of details to include on university applications and on potential career paths.” 

The Connect & Contribute Scheme, which is supported by Social Responsibility Catalyst Fund from the School of Environment, Education and Development within the University of Manchester, is now in its second year.  

One young person who was mentored in the first year of the scheme said:  

“It has been interesting and helpful discussing university topics, especially with a student who has experience in university life.” 

Another commented: 

“I still feel overwhelmed about going to university and living all by myself, but the meeting encouraged me to accept changes with a positive mindset.” 

A MA Digital Technologies, Communication and Education degree student who was one of the scheme mentors said: 

“I had the privilege of supporting Year 12 students from nearby secondary schools, helping them build confidence and offering insights into university applications, student life, and the overall university experience. It’s been a truly rewarding experience to share my journey and offer guidance to students exploring their academic futures.” 

Sixth form students who were mentored in the first year of Connect & Contribute will be sitting their A Levels this year and it’s hoped that many of them will be on their way to university, with some of them possibly set to become University of Manchester students in 2026-27.

The recovery plan launched in January 2023 after one of the most testing years in NHS history with a perfect storm of pressures resulting in overwhelmed A&E departments, and significant numbers of patients waiting over 12-hours for beds.

Using national performance data, the 91ֱ�� team show that initial improvements in the 4-hour and 12-hour waiting time targets and in the category two ambulance response times were achieved in the 12 months after the plan was announced. These initial performance improvements have since plateaued.

said: “A core aim of the recovery plan was to bring people together to coordinate a unified whole system response to tackle urgent and emergency care performance. This has happened – though the complexity of meeting national targets, addressing local challenges and responding to rising demand means that many systems have been running to stand still.”

The recovery plan set out a number of ambitions, including:

• Improve to 76% of patients being admitted, transferred or discharged within four hours by March 2024.

• Improve ambulance response times for Category 2 incidents to 30 minutes on average over 2023/24.

During the period the recovery plan was implemented, the trend of declining performance for 4-hour waits and 12-hour waits was arrested, and performance improved across 4-hour waits, 12-hour waits and Category 2 ambulance response time between February and September 2023.

However, following September 2023, initial rates of improvement were not maintained across the different indicators, and performance plateaued. The findings demonstrate that meaningful improvement towards the set targets takes time to deliver, especially in the context of rising volumes in ED, experienced over this period.

The 91ֱ�� team found that successful and sustainable change depends not only on service developments but also on three broad enablers - improved communication, partnership working, and visible and present leadership - identified via in-depth key informant interviews conducted as part of the evaluation.

said “Our real-time evaluation of the impact of the 2023 recovery has provided crucial insights that have informed current and future winter planning. This demonstrates the value of NIHR’s investment in independent, rapid and responsive evaluation to inform decision-making and future service delivery.”

The report Independent evaluation of the 2023-2025 NHS Delivery Plan for Recovering Urgent and Emergency Care Services, including prioritisation of the high-impact initiatives is available .

Professors , , , ,  and have all been awarded what is regarded as one of the highest honours for health and social care researchers in the UK.

Senior Investigators are among the most outstanding and influential researchers funded by NIHR. They are recognised for the quality and global reach of their research. They also help mentor the next generation, strengthen research culture and embed inclusion.

, is Professor of Critical Care Medicine, Vice Dean for Health and Care Partnerships and Research Professor at the Humanitarian and Conflict Response Institute at The University of Manchester.

He is also a Critical Care Consultant at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust and based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

He said: “I am delighted to be appointed as a NIHR Senior Investigator for a second term. This national award will allow me continue to provide a systems voice from Greater 91ֱ�� to help influence national research policy in applied health, social care, and public health, and to act as an international ambassador for the National Institute of Health and Care Research."

is the first ever NIHR Research Professor in Digital Mental Health in the UK and a Professor of Clinical Psychology at The University of Manchester. 

She co-founded spinout company CareLoop Health, a UK digital therapeutics company developing AI-powered tools to monitor symptoms, predict relapse, and deliver personalised care for people with severe mental illnesses like psychosis.

She is also based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

She said: “This NIHR Senior Investigator award will provide an important platform to advance my research in digital mental health and to strengthen the evidence base for innovative approaches that improve care for people with severe mental health problems. I hope it will support closer partnerships with service users, clinicians and services, and help drive research that delivers meaningful impact in routine practice.”

' research focuses on Data Science and Health Services using large-scale primary care databases. 

He is an expert in  computational statistics and machine learning  and has a long track record in research using large-scale primary care and other administrative databases to investigate quality of care, mortality and cardiovascular disease, with a focus on the effects of policy changes and the role of socio-economic and regional disparities

He said: “I’m delighted to receive this NIHR Senior Investigator award. It recognises the collective efforts of my collaborators and provides an exciting opportunity to accelerate our work using real‑world health data to improve the quality and equity of care. This support will help us drive forward innovative, policy‑relevant research in primary care and population health, ensuring it has the greatest possible benefit for patients and communities.

is Professor of Rheumatology at The University of Manchester and Honorary Consultant Rheumatologist at 91ֱ�� Royal Infirmary, part of Manchester University NHS Foundation Trust.

Prof Buch is also Chief Investigator for the Medical Research Council (MRC) and British Heart Foundation UK CARDIO-IMID Partnership and Chair for the MRC-NIHR 'Efficacy, Mechanism, Evaluation' Programme.She is also based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

She said: "I am delighted to be re-awarded the NIHR Senior Investigator Award. This award strengthens my ongoing commitment to advancing research that improves outcomes for people living with rheumatic and musculoskeletal diseases. I warmly welcome this support, which will help advance our scientific goals, foster meaningful collaboration and help translate innovative discoveries into real-world clinical benefit"

is Professor of Psychiatry and Director of Global Mental Health Research at The University of Manchester and Director of the Global Centre for Research on Mental Health Inequalities and an Honorary Consultant at Mersey Care NHS Foundation Trust.

He is also based at the National Institute for Health and Care Research (NIHR) 91ֱ�� Biomedical Research Centre (BRC)

Professor Lucy Chappell, Chief Executive Officer of the NIHR and Chief Scientific Adviser at the Department of Health and Social Care, said: “By recognising leaders across the breadth of health and care, we are reinforcing NIHR's commitment to supporting excellence wherever it is found and ensuring that research leadership mirrors the communities and professions it serves.

“Senior Investigators make a significant impact to the NIHR and the wider research landscape and I look forward to seeing the contributions and impact they make across health and care research.”

Researchers are awarded Senior Investigator status based on their contributions to the NIHR and their leadership of high-quality, internationally recognised research.

As outstanding leaders of patient and people-based research, NIHR Senior Investigators serve on NIHR funding committees and boards and provide leadership at a regional or national level.

They serve as NIHR ambassadors, demonstrate research excellence, contribute to national growth, and champion the involvement of patients and communities into research.

Hosted by 91ֱ�� Metropolitan University, in partnership with The University of Manchester, Greater 91ֱ�� Combined Authority (GMCA), The Growth Company, and University of Salford, the flagship Made in Greater 91ֱ�� event demonstrated how coordinated regional action is accelerating delivery of the Government’s Modern Industrial Strategy.

Recent national data shows that Greater 91ֱ�� is the UK’s fastest growing city region, with productivity growth outpacing national averages for more than a decade.

The city region has long been recognised as a testbed for the future UK economy, bringing together universities, business and civic partners to tackle national challenges at regional scale.

That collaborative model now supports Greater 91ֱ��’s approach to good growth, as it leads the UK’s ambitions in – advanced materials and manufacturing; creative industries; digital, cyber and AI; health innovation and life sciences; and low carbon.

These are aligned to five of the sectors identified as having the greatest potential for growth in the Modern Industrial Strategy.

Professor Steve Rothberg, Provost and Deputy Vice-Chancellor at 91ֱ�� Met, said: “With universities acting as powerful anchor institutions for growth, there has never been a more important time to connect, collaborate and drive collective impact.

“Here in Greater 91ֱ��, we have a long tradition of being at the forefront of innovation. This event was a fantastic opportunity for organisations across the city-region to come together and re‑emphasise this commitment while exploring future ways to deliver for the UK.”

Speakers at the event outlined how universities, industry and civic partners are aligning investment, skills pipelines, research strengths and business support to accelerate the industrial strategy in real time.

By uniting academic expertise, cutting edge R&D facilities, industry ambitions and civic leadership, Greater 91ֱ�� is building the environment required for long term national competitiveness.

Professor John Holden, Vice-President for Civic Engagement and Innovation, said: "Yesterday’s Made in Greater 91ֱ�� event showed exactly what our city‑region does best by bringing universities, industry and civic partners together to drive innovation. Our universities must ensure that innovation fuels growth that is fast, ambitious and inclusive so the benefits of our progress as a region are shared across every community.

"Through the University’s innovation arm, Unit M, we are partnering with the Industrial Strategy Advisory Council to ensure this collaboration shapes national priorities. Our recently launched deep tech accelerator is a demonstration of a cross-Greater 91ֱ�� initiative with shared purpose and dedicated resources to boost innovation. 

"We are also working with GMCA and Rochdale Development Agency to scope out the next phase of development of the Sustainable Materials and Manufacturing Centre (SMMC), the first major development in the Atom Valley Mayoral Development Zone. Through the Cambridge x 91ֱ�� Partnership we’re proving that our ambition and impact extends well beyond the region, strengthening national capability through collaboration between two of the UK’s most globally recognised innovation ecosystems."

Speaking at the event, Jo Ahmed MBE, Practice Senior Partner at Deloitte, said: “What we do brilliantly in this city region is that we come together across the public and private sectors and academia to deliver impact and, importantly, to deliver action.

“When I speak to national and international colleagues, they all want to know what it is we are doing in Greater 91ֱ�� to create the growth we are seeing here. My answer is that it’s a blend of the spirit this place, it’s how we connect, how we collaborate, and how we support each other for collective long term growth and opportunity.

“I am truly optimistic about the future opportunities that can be delivered through a continued place-based approach to deliver the Modern Industrial Strategy and Greater 91ֱ�� Sector Development Plans, and to continue that collaboration between sectors to benefit the broadest possible cross section of businesses and the communities around us.”

Current drug delivery methods often struggle to target anti cancer treatments precisely at tumour sites, leading to unwanted effects elsewhere in the body. 91ֱ��’s snail inspired robots aim to change this by delivering therapies only where they are needed, with highly targeted, region-specific precision.

By reliably anchoring themselves within malignant tissues and releasing their therapeutic cargo in a controlled manner, the robots are expected to increase drug bioavailability at tumour sites, significantly reduce off target toxicity and improve patient outcomes.

The project – funded through UKRI’s Cross Research Council Responsive Mode (CRCRM) scheme, which supports emerging research that transcends disciplines – aims to transform colorectal cancer treatment by enabling highly targeted drug release directly at tumour sites.

Drawing inspiration from the slow, controlled and highly adaptable movements of snails and slugs, the research team will mimic the animals’ unique slime based locomotion, powered by rhythmic muscular waves and adhesive mucus, to engineer mini robots capable of navigating the gastrointestinal tract with exceptional accuracy.

Snail locomotion has long intrigued evolutionary biologists and roboticists, but its biomechanics remain under explored. This project will generate the first high resolution experimental datasets on snail movement, mucus interactions and foot actuation, enabling the team to build advanced digital simulations and machine learning driven control systems.

These biological insights will underpin the design of a new class of biocompatible soft robots, constructed from peptide based bionanomaterials that can be finely tuned at the molecular level. Engineered to respond to benign external triggers such as magnetic fields, the materials will enable non invasive, remote control of the robotic devices once inside the body.

The project will also create a multiscale digital twin simulation framework, integrating biomechanics, robotics, bionanomaterials and cancer biology. This virtual testing environment will accelerate design optimisation, reduce laboratory costs, and allow researchers to model robot–tissue interactions before clinical translation.

While the primary goal is to deliver advances in colorectal cancer treatment, the technology has potential applications far beyond oncology. The soft robots could serve as alternatives to capsule endoscopy, offer new solutions for environmental and industrial microrobotics, and enable safer operation in complex environments - from pipe inspection to sustainable agri food systems.

The project reflects The University of Manchester’s leadership in engineering biology and its commitment to pioneering research with real world health impact.

Read further papers related to this research:

• Charge Directed Selective Co‐Assembly of Ionic Complementary Peptide Binary Mixtures
  DOI:
• Harnessing 3D microarchitecture of pterosaur bone using multi-scale X-ray CT for aerospace material design
  DOI:
• Scalability of resonant motor-driven flapping wing propulsion systems
  DOI:
• The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion
  DOI:
• Energy and time optimal trajectories in exploratory jumps of the spider Phidippus regius
  DOI:

The study found SEND complaints make up 27% of the complaints received by the LGSCO and 48% of the cases that it upholds. Common issues include delays in carrying out Education, Health and Care Plan (EHCP) assessments, and failures to deliver the support children are legally entitled to.

Despite these challenges, the research also points to the impact of the Ombudsman’s work. Its recommendations can help councils identify problems, strengthen accountability, and push for improvements that benefit families.

In some cases, the findings have empowered local officials to argue for more resources or rethink how services are delivered - however, the report also highlights limitations including the time and capacity required to respond to investigations, and repeated recommendations on issues councils recognise but lack the means to resolve.

A key gap identified is that the Ombudsman cannot investigate complaints directly against schools - even though they play a central role in delivering SEND support - which can leave families without clear routes to resolve issues.

The report sets out recommendations to strengthen the system, which include extending the Ombudsman’s powers to cover schools, raising awareness of joint investigations with health bodies, and improving communication between councils and the Ombudsman. Crucially, it emphasises that meaningful reform must address underlying pressures on the SEND system, including funding shortages and workforce gaps.

“This research comes at a key moment for SEND system reform,” said Ash Patel, Programme Head for Justice at the Nuffield Foundation. “The Government’s intention to improve complaints and mediation processes - enabling faster and more collaborative, resolution of disagreements and reducing the need for appeals to the SEND Tribunal - is welcome. However, the proposals are silent on the role of the LGSCO, and it remains frustratingly unclear how disputes will be avoided or how routes for appeals and complaints will operate.”

“The report points to high levels of tension between the education system and families of children with SEND; without greater attention to minimising these conflicts, it is difficult to see how existing pressures on complaints and appeals will ease.”